342 related articles for article (PubMed ID: 20001212)
1. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Schwock J; Dhani N; Hedley DW
Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
[TBL] [Abstract][Full Text] [Related]
2. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase: a potential target in cancer therapy.
van Nimwegen MJ; van de Water B
Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Schultze A; Fiedler W
Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction by focal adhesion kinase in cancer.
Zhao J; Guan JL
Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797
[TBL] [Abstract][Full Text] [Related]
6. FAK expression regulation and therapeutic potential.
Li S; Hua ZC
Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
[TBL] [Abstract][Full Text] [Related]
7. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
8. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention.
Parsons JT; Slack-Davis J; Tilghman R; Roberts WG
Clin Cancer Res; 2008 Feb; 14(3):627-32. PubMed ID: 18245520
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T
Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768
[TBL] [Abstract][Full Text] [Related]
11. FAK signaling in neoplastic disorders: a linkage between inflammation and cancer.
Mon NN; Ito S; Senga T; Hamaguchi M
Ann N Y Acad Sci; 2006 Nov; 1086():199-212. PubMed ID: 17185517
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
13. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.
Cox BD; Natarajan M; Stettner MR; Gladson CL
J Cell Biochem; 2006 Sep; 99(1):35-52. PubMed ID: 16823799
[TBL] [Abstract][Full Text] [Related]
14. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Brenner W; Greber I; Gudejko-Thiel J; Beitz S; Schneider E; Walenta S; Peters K; Unger R; Thüroff JW
Int J Oncol; 2008 May; 32(5):1125-31. PubMed ID: 18425341
[TBL] [Abstract][Full Text] [Related]
15. Integrin-regulated FAK-Src signaling in normal and cancer cells.
Mitra SK; Schlaepfer DD
Curr Opin Cell Biol; 2006 Oct; 18(5):516-23. PubMed ID: 16919435
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase as a target in the treatment of hematological malignancies.
Yin B
Leuk Res; 2011 Oct; 35(10):1416-8. PubMed ID: 21592572
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
[TBL] [Abstract][Full Text] [Related]
19. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
20. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
